4.51 USD
▲-0.23+6.12%
盘后 4.24 -0.24%
2026-08-03
市值
$1.02B
市盈率
—
EPS
-2.23
股息率
—
52 周区间
3.16 – 7.98
成交量
1.02M
Beta
0.89
目标价
15.13
52W 低 3.1652W 高 7.98
价格走势
公司简介
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the tr...